Endocyte Shares Plunge After Drug Trial Is Stopped for FutilityBusinessweekEndocyte (ECYT:US) Inc., with no marketed products, plunged 58 percent in early trading after the drug it’s developing with Merck & Co.’s backing failed to help patients in a trial for ovarian cancer. The phase III study was stopped after an analysis showed that …Merck, Endocyte halt study of ovarian cancer drugMarketWatchMerck, Endocyte Halt Study of Ovarian Cancer TreatmentWall Street JournalMerck and Endocyte’s ovarian cancer drug fails in trialReutersRTT News -FierceBiotech -TheStreet.comall 14 news articles …Read Full Story
Endocyte Shares Plunge After Drug Trial Is Stopped for Futility - Businessweek
Real Estate of Cebu
